NCT05722171 - Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

December 27, 2023

Study Completion Date

December 27, 2024

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Interventions

BIOLOGICAL

gdT cell injection targeting B7-H3 chimeric antigen receptor

The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 1E8, 2E8 and 4E8 CAR-gdT groups in order of sequence. And the subjects will be administered once.

Trial Locations (1)

230088

RECRUITING

PersonGen Anke Cellular Therapeutice Co., Ltd., Hefei